ReviewMolecules (Basel, Switzerland)2017
Evolution of Complex Target SELEX to Identify Aptamers against Mammalian Cell-Surface Antigens.
Review in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 78 citations in OpenAlex.
- Unraveling Bacterial Single-Stranded Sequence Specificities: Insights from Molecular Dynamics and MMPBSA Analysis of Oligonucleotide Probes.Molecular biotechnology · 2024Review
- Recent Advances in DNA Nanomaterials.Nanomaterials (Basel, Switzerland) · 2023Review
- Lipid and Peptide-Oligonucleotide Conjugates for Therapeutic Purposes: From Simple Hybrids to Complex Multifunctional Assemblies.Pharmaceutics · 2023Review
- Analytical methods for microplastics in the environment: a review.Environmental chemistry letters · 2023Review
- AnBiochemistry · 2022Article
- Aptamers as Theragnostic Tools in Prostate Cancer.Biomolecules · 2022Review
- The Evolution of Molecular Recognition: From Antibodies to Molecularly Imprinted Polymers (MIPs) as Artificial Counterpart.Journal of functional biomaterials · 2022Review
- Enhancing CAR-T Cell Therapy with Functional Nucleic Acids.ACS pharmacology & translational science · 2021Review
- Development and characterization of a DNA aptamer for MLL-AF9 expressing acute myeloid leukemia cells using whole cell-SELEX.Scientific reports · 2021Article
- Hybrid-Type SELEX for the Selection of Artificial Nucleic Acid Aptamers Exhibiting Cell Internalization Activity.Pharmaceutics · 2021Article
- Utility of Multivalent Aptamers to Develop Nanoscale DNA Devices against Surface Receptors.ACS omega · 2021Review
- The Landscape of RNA-Protein Interactions in Plants: Approaches and Current Status.International journal of molecular sciences · 2021Review
- Recent Advancements in Electrochemical Biosensors for Alzheimer's Disease Biomarkers Detection.Current medicinal chemistry · 2021Review
- Dimeric and Multimeric DNA Aptamers for Highly Effective Protein Recognition.Molecules (Basel, Switzerland) · 2020Review
- Diagnosis of scrub typhus: recent advancements and challenges.3 Biotech · 2020Review
- Ligand Guided Selection (LIGS) of Artificial Nucleic Acid Ligands against Cell Surface Targets.ACS applied bio materials · 2020Article
- Ligand-Guided Selection with Artificially Expanded Genetic Information Systems against TCR-CD3ε.Biochemistry · 2020Article
- Internalized Functional DNA Aptamers as Alternative Cancer Therapies.Frontiers in pharmacology · 2020Review
- Integrating Ligand-Receptor Interactions and In Vitro Evolution for Streamlined Discovery of Artificial Nucleic Acid Ligands.Molecular therapy. Nucleic acids · 2019Article
- Aptamer and nanomaterial based FRET biosensors: a review on recent advances (2014-2019).Mikrochimica acta · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The demand has increased for sophisticated molecular tools with improved detection limits. Such molecules should be simple in structure, yet stable enough for clinical applications. Nucleic acid aptamers (NAAs) represent a class of molecules able to meet this demand. In particular, aptamers, a class of small nucleic acid ligands that are composed of single-stranded modified/unmodified RNA/DNA molecules, can be evolved from a complex library using Systematic Evolution of Ligands by EXponential enrichment (SELEX) against almost any molecule. Since its introduction in 1990, in stages, SELEX technology has itself undergone several modifications, improving selection and broadening the repertoire of targets. This review summarizes these milestones that have pushed the field forward, allowing researchers to generate aptamers that can potentially be applied as therapeutic and diagnostic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.